{"id":379960,"date":"2020-11-12T10:50:01","date_gmt":"2020-11-12T15:50:01","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379960"},"modified":"2020-11-12T10:50:01","modified_gmt":"2020-11-12T15:50:01","slug":"dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/","title":{"rendered":"Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market"},"content":{"rendered":"

<\/p>\n

Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market<\/b><\/p>\n

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE<\/a>)–
\nDr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin\u00ae (Succinylcholine Chloride) Injection, 20 mg\/mL, approved by the U.S. Food and Drug Administration (USFDA).\n<\/p>\n

\nThe Quelicin\u00ae brand and generic market had U.S. sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health*.\n<\/p>\n

\nDr. Reddy\u2019s Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL), is available in multi-dose vials.\n<\/p>\n

\nPlease see full prescribing information including boxed warning.
\n
https:\/\/www.drreddys.com\/pi\/succinylcholine-chloride.pdf<\/a><\/p>\n\n\n
\n

WARNING<\/b><\/p>\n

RISK OF CARDIAC ARREST FROM HYPERKALEMIC RHABDOMYOLYSIS<\/b><\/p>\n

\nThere have been rare reports of acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest and death after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne’s muscular dystrophy.\n<\/p>\n

\n\u00a0\n<\/p>\n

\nThis syndrome often presents as peaked T-waves and sudden cardiac arrest within minutes after the administration of the drug in healthy appearing pediatric patients (usually, but not exclusively, males, and most frequently 8 years of age or younger). There have also been reports in adolescents.\n<\/p>\n

\n\u00a0\n<\/p>\n

\nTherefore, when a healthy appearing infant or child develops cardiac arrest soon after administration of succinylcholine, not felt to be due to inadequate ventilation, oxygenation or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. This should include administration of intravenous calcium, bicarbonate, and glucose with insulin, with hyperventilation. Due to the abrupt onset of this syndrome, routine resuscitative measures are likely to be unsuccessful. However, extraordinary and prolonged resuscitative efforts have resulted in successful resuscitation in some reported cases. In addition, in the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently.\n<\/p>\n

\n\u00a0\n<\/p>\n

\nSince there may be no signs or symptoms to alert the practitioner to which patients are at risk, it is recommended that the use of succinylcholine in pediatric patients should be reserved for emergency intubation or instances where immediate securing of the airway is necessary, e.g., laryngospasm, difficult airway, full stomach, or for intramuscular use when a suitable vein is inaccessible (see PRECAUTIONS:<\/b>Pediatric Use<\/b> and DOSAGE AND ADMINISTRATION<\/b>).\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nQuelicin\u00ae is a trademark of Hospira, Inc\n<\/p>\n

\n*IQVIA Retail and Non-Retail MAT September 2020\n<\/p>\n

\nRDY-0820-308\n<\/p>\n

About Dr. Reddy\u2019s<\/b>: Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products \u2013 Dr. Reddy\u2019s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy\u2019s operates in markets across the globe. Our major markets include \u2013 USA, India, Russia & CIS countries, and Europe. For more information, log on to:www.drreddys.com<\/a><\/p>\n

\nDisclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management\u2019s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency \/ severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and\/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, <\/span><\/b>and (vi) the susceptibility of our industry and the markets addressed by our, and our customers\u2019, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein.\u201d\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201112005793\/en\/<\/a><\/span><\/p>\n

INVESTOR RELATIONS
\n<\/b>
AMIT AGARWAL amita@drreddys.com
\n<\/span>
(PH: +91-40-49002135)\n<\/p>\n

MEDIA RELATIONS
\n<\/b>
APARNA TEKURI
\n
aparnatekuri@drreddys.com
\n<\/span>
(PH: +91-40- 49002446)\n<\/p>\n

KEYWORDS:<\/b> United States India North America Asia Pacific New Jersey<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Pharmaceutical<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)– Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin\u00ae (Succinylcholine Chloride) Injection, 20 mg\/mL, approved by the U.S. Food and Drug Administration (USFDA). The Quelicin\u00ae brand and generic market had U.S. sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health*. Dr. Reddy\u2019s Succinylcholine Chloride Injection USP, 200 mg\/10 mL … <\/p>\n

Continue reading “Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379960","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)– Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin\u00ae (Succinylcholine Chloride) Injection, 20 mg\/mL, approved by the U.S. Food and Drug Administration (USFDA). The Quelicin\u00ae brand and generic market had U.S. sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health*. Dr. Reddy\u2019s Succinylcholine Chloride Injection USP, 200 mg\/10 mL … Continue reading "Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T15:50:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\\\/10 mL (20 mg\\\/mL) in the U.S. Market\",\"datePublished\":\"2020-11-12T15:50:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/\"},\"wordCount\":859,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/\",\"name\":\"Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\\\/10 mL (20 mg\\\/mL) in the U.S. Market - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-11-12T15:50:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\\\/10 mL (20 mg\\\/mL) in the U.S. Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/","og_locale":"en_US","og_type":"article","og_title":"Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market - Market Newsdesk","og_description":"Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)– Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin\u00ae (Succinylcholine Chloride) Injection, 20 mg\/mL, approved by the U.S. Food and Drug Administration (USFDA). The Quelicin\u00ae brand and generic market had U.S. sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health*. Dr. Reddy\u2019s Succinylcholine Chloride Injection USP, 200 mg\/10 mL … Continue reading \"Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T15:50:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market","datePublished":"2020-11-12T15:50:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/"},"wordCount":859,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/","name":"Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-11-12T15:50:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201112005793r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-laboratories-announces-the-launch-of-succinylcholine-chloride-injection-usp-200-mg-10-ml-20-mg-ml-in-the-u-s-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379960"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}